Clinical trial of Methyl-prednisolone pulse conbined therapy for Refractory Kawasaki Disease: Trial in Single Institution

Clinical trial of Methyl-prednisolone pulse conbined therapy for Refractory Kawasaki Disease: Trial in Single Institution - Clinical trial of sterid pulse conbined therapy for Kawasaki Disease

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000005021

Enrollment

Registered

2011-02-05

Start date

2007-04-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Kawasaki diease

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: All patients were Japanese and fulfilled the Criteria for Diagnostic Guidelines for Kawasaki Disease (5th revision) published by the Kawasaki Disease Research Committee in Japan.

Exclusion criteria

Exclusion criteria: Exclusion criteria included a previous diagnosis, the presence of coronary artery aneurysms, and other contraindications to steroid therapy.

Design outcomes

Primary

Measure	Time frame
First outcome defined a antipyretic potency at 36 hours after completion of the initial treatment.	—

Secondary

Measure	Time frame
Second outcome defined a envaluation of coronary artery at 36 hours and 1 month after the end of thrapy.	—

Countries

Japan

Outcome results